Rising Popularity of Anti-Wrinkle Products Fuels Asia, Europe, and South America Anti-Aging Market
Rising Popularity of Anti-Wrinkle Products Fuels Asia, Europe, and South America Anti-Aging Market
This press release was orginally distributed by SBWire
Albany, NY — (SBWIRE) — 02/13/2017 — A new Transparency Market Research report states that the Asia, Europe, and South America anti-aging market was valued at US$15.3 bn in 2012 and is predicted to reach US$30.9 bn in 2020. It is expected to expand at a CAGR of 9.30{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} from 2014 to 2020. The title of the report is “Asia, Europe, and South America Anti-aging Market – Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020”.
Obtain the Sample Report of Asia, Europe, and South America Anti-Aging Market at: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5021
As per the report, the anti-aging market in Asia, Europe, and South America is majorly fuelled by the increasing number of baby boomers, thus increasing the demand for various methods of curbing and reversing the prominent signs of aging. The market is continuously growing and a number of products, devices, and services have entered the market in recent years due to the consistent demand to lessen the signs of aging. Amongst these, in 2013, the anti-aging products held the biggest share in the anti-aging market due to increasing awareness amongst people and the economical prices of these products.
On the basis of product type, the market is segmented into dermal fillers, UV absorbers, botox, anti-stretch products, anti-wrinkle products, and hair color. Amongst these, in 2013, anti-wrinkle products held the biggest share in the anti-aging products market in Asia. The anti-wrinkle product segment stood at more than US$8.1 bn in Asia in 2013. This is due to the broad range of anti-wrinkle products available in the market and the rising awareness owing to a number of promotional campaigns held in Asia. Anti-wrinkle products also held the largest share in Europe in the same year. The demand for these products is high in European countries owing to their increasing availability at economical prices.
On the basis of service, the market is segmented into anti-adult acne therapy, anti-pigmentation therapy, liposuction, chemical peel, abdominoplasty, hair restoration therapy, sclerotherapy, and eyelid surgery. The anti-aging services market is expanding swiftly in Europe on account of the rising disposable income of consumers owing to ongoing recovery from the economic crisis in Europe. Within Europe, the anti-aging services market in Italy held the biggest share in 2013 owing to increasing demand for hair restoration treatments and breast augmentation. The anti-aging services market is predicted to record the highest growth rate in Spain in the forecast horizon due to the rising aging population and the increasing prevalence of obesity.
Read the Current Market Analysis of Asia, Europe, and South America Anti-aging at: http://www.transparencymarketresearch.com/asia-europe-south-america-anti-aging-market.html
On the basis of device type, the market is segmented into microdermabrasion devices, anti-cellulite treatment devices, radio frequency devices, and laser aesthetic devices. Anti-aging devices are the most prevalent in South American countries. Radiofrequency devices and laser aesthetic devices held the biggest share in South America, especially in Brazil, due to their high effectiveness and safety.Alma Laser Ltd., Allergan, Inc., Beiersdorf AG, Cynosure, Inc., Coty, Inc., L’Oreal SA, Valeant Pharmaceutical International, Inc., Solta Medical, Inc., and PhotoMedex, Inc., among others, are the major players dominant in the market.
About TMR
Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
For more information on this press release visit: http://www.sbwire.com/press-releases/asia-europe-and-south/release-770146.htm
Media Relations Contact
Rohit Bhisey
Head
Email: Click to Email Rohit Bhisey
Web: http://www.transparencymarketresearch.com/asia-europe-south-america-anti-aging-market.html
Read more: http://www.digitaljournal.com/pr/3234223#ixzz4bMEMlRjj
- Published in Blog, Life Sciences, News Home, Sirona Biochem
The 2017 Standards of Medical Care in Diabetes: an update from the ADA
The 2017 Standards of Medical Care in Diabetes: an update from the ADA
The American Diabetes Association (ADA) has released the 2017 update to its Standards of Medical Care in Diabetes (Standards).1 The document is reviewed each year by a multidisciplinary committee of experts in diabetes care, which examines relevant research that informs the revisions.
“The most recent update to the ADA Standards of Medical Care addresses many new and important issues regarding the management of patients with diabetes,” said Kevin M. Pantalone, DO, staff endocrinologist and director of clinical research at the Cleveland Clinic Foundation. The 2017 Standards contain the usual guidelines pertaining to type 2 diabetes prevention and the diagnosis and treatment of type 1, type 2, and gestational diabetes. Additionally, Dr Pantalone identified several of the most notable updates.
One recommendation suggests considering metabolic surgery for patients with obesity and uncontrolled type 2 diabetes who have a body mass index (BMI) as low as 30 kg/m2 (27.5 kg/m2for Asian Americans). This update is based on a growing body of research showing that metabolic surgery — previously referred to as bariatric surgery — leads to improved glycemic control and reduced cardiovascular disease (CVD) risk in this patient population compared with other medical and lifestyle interventions.2 The committee also noted that the safety of metabolic surgery has significantly improved in the past 2 decades: Related mortality rates are 0.1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} to 0.5{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}, which are similar to the rates associated with hysterectomy or cholecystectomy.2
Another update recommends considering 2 specific glucose-lowering therapies (glucagon-like peptide-1 [GLP-1] receptor agonists or sodium-glucose cotransporter-2 [SGLT2] inhibitors) for high-risk patients with CVD who have type 2 diabetes, which is in line with the findings of recently published clinical trials, including the EMPA-REG OUTCOME (ClinicalTrials.gov identifier: NCT01131676) and LEADER (ClinicalTrials.gov identifier: NCT01179048) trials.
The EMPA-REG OUTCOME study examined the effects of the SGLT2 inhibitor empagliflozin vs placebo and usual care in high-risk patients with CVD who have diabetes.3 The findings show that the drug led to a 14{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} reduction in the composite outcome of myocardial infarction (MI) and stroke, and a 38{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} reduction in CV death over a median follow-up period of 3.1 years.3 As a result, the US Food and Drug Administration (FDA) added a new indication for empagliflozin to reduce CV mortality risk in adults with type 2 diabetes and heart disease.4 In a similar manner, results from the LEADER trial showed that the GLP-1 receptor agonist liraglutide resulted in fewer MI, stroke, or CV deaths compared with placebo (13{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} vs 14.9{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}) over a median follow-up period of 3.8 years.5
The committee also sought to further define hypoglycemia. The update indicates that a level of lower than 54 mg/dL (3.0 mmol/L) should be considered serious, clinically important hypoglycemia, even in the absence of symptoms. It is recommended that values below this level be reported in clinical trials and practice. Previous recommendations defined hypoglycemia in hospitalized patients as blood glucose levels <70 mg/dL (3.9 mmol/L) and severe hypoglycemia as levels <40 mg/dL (2.2 mmol/L). Severe hypoglycemia is now defined as “that associated with severe cognitive impairment regardless of blood glucose level,” and a level ≤70 mg/dL “is considered an alert value and may be used as a threshold for further titration of insulin regimens,” according to the Standards.
“Also, and perhaps most important, is the Standards’ acknowledgment and addressing of the socioeconomic aspects of diabetes management: medication cost and self-management support,” Dr Pantalone added. “These areas had been inadequately addressed by earlier versions of the guideline.”
The new version includes 2 detailed tables that provide the estimated monthly cost of various glucose-lowering medications, and the section on reducing disparities in diabetes care states that community health workers, peers, and lay leaders can facilitate the delivery of diabetes self-management education (DSME) and support services. “Strong social support leads to improved clinical outcomes, a reduction in psychosocial issues, and adoption of healthier lifestyles,” the committee noted.
Other notable additions include recommendations pertaining to screening and mental health referrals for patients with depression, anxiety, diabetes distress, eating disorders, and other psychological issues; greater emphasis on assessing comorbidities in patients with diabetes, and an expanded list of such comorbidities, including mental disorders as well as autoimmune disease and HIV; a new physical activity recommendation to break up sedentary behavior every 30 minutes to reduce associated behaviors illuminated by recent research; and increased options for both glucose management and hypertension treatment.
“The ADA has done a fantastic job of remaining on top of the new advances in diabetes management, incorporating new findings and recommendations into the guidelines in a timely manner, but doing so only after a thorough and vigorous review of the recently published medical literature,” said Dr Pantalone.
References
- American Diabetes Association. Standards of medical care in diabetes–2017. Diabetes Care. 2017;40(Suppl. 1):S6-S10.
- Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39(6):861-77.
- Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373:2117-2128.
- FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes [news release]. Silver Spring, MD: FDA; December 2, 2016. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm. Accessed January 18, 2017.
- Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.
- Published in Bio technology, Blog, Life Sciences, Sirona Biochem
Sirona Biochem Announces Convertible Note Financing
VANCOUVER, BC–(Marketwired – January 31, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announced today a non-brokered private placement (the “Private Placement”) of convertible notes (“Notes”) for gross proceeds of up to $600,000. Each Note will be convertible at the option of the holder into one common share of the company at a conversion price of $0.18 per share during the 18 month term of the Notes.
The Notes will mature in 18 months from the date of issuance and bear interest at the rate of 12{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} per annum, payable quarterly, until the Notes are converted or repaid. The company will be entitled to repay the principal amount of the Notes, together with accrued and unpaid interest, at any time commencing four months after the date of issuance, subject to giving the holders prior notice thereof to permit holders to convert during the notice period. The Notes are unsecured and transferable, subject to resale restrictions under applicable securities laws and TSX Venture Exchange requirements.
Sirona Biochem intends to use the net proceeds from the Private Placement for general working capital, and to support the company’s efforts to secure a licensing agreement for its skin lightening compound, TFC-1067. The company is expecting to receive a term sheet for a licensing transaction for TFC-1067 in Q1 2017 but there can be no assurances that a licensing agreement will be entered into on terms acceptable to Sirona Biochem or at all. The Company may pay fees of 7{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} in cash to qualified finders.
All securities issued in connection with the private placement will be subject to a statutory hold period of four months commencing from the date of issuance of the Notes. Closing of the private placement is subject to customary conditions, including TSX Venture Exchange acceptance.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.
In addition, the Company announces an extension to the term of 8,865,970 common share purchase warrants (the “Warrants”) originally issued on March 6, 2014. The warrants were issued as part of a private placement. The expiry dates will be extended as follows:
March 6, 2014
Number of Warrants: | 8,865,970 |
Original Expiry Date of Warrants: | March 6, 2017 |
New Expiry Date of Warrants: | April 30, 2017 |
Exercise Price of Warrants: | $0.20 |
All other terms of the Warrants will remain unchanged.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: a third party potential licensees of TFC-1067 may not deliver a term sheet to the company in Q1 2017 or at all; the company may not be able to negotiate a license agreement with a potential licensees of TFC-1067 on terms acceptable to Sirona Biochem; the progress and timing of its clinical trials are uncertain; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing products; unexpected adverse side effects or inadequate therapeutic efficacy of the company’s or licensed products that could delay or prevent product development or commercialization; the scope and validity of patent protection for the company’s or licensed products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
CONTACT INFORMATION
-
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, News Home, Sirona Biochem
Sirona Biochem (SBM:tsxv) CEO’s Report on Progress
Sirona Biochem CEO’s Report on Progress
– Momentum Public Relations –
Press Release: December 8, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) today provided a business update.
Dear Shareholders,
The following is an update on our progress in 2016 and our plans for 2017.
Skin Lightener, TFC-1067
Throughout 2016, we have remained focused on completing a licensing agreement for our skin lightening compound, TFC-1067. It was our plan to finalize this transaction earlier in the year. However, it is not a timeline we have full control over. We have multiple companies engaged and progressing through due diligence at their own speed. Despite contrary market rumors, no party has left the negotiation table. At this time, we expect to receive one or more term sheets from interested parties before the end of Q4 2016. We remain very confident that one or more of these global entities will move forward with a definitive licensing agreement in early 2017.
Should the circumstances be that no potential licensing partner can complete the deal in a reasonable time frame, or for what we consider to be an appropriate value, then we will proceed with the full development of the skin lightener on our own. This would include GMP scale-up, toxicology, formulation and an early clinical trial. We already have consultants in France building the full development plan. We are aware that building a development plan may seem unnecessary but we take seriously our commitment to minimize risk and maximize opportunity for our shareholders. It is important that we are not dependent on a partner to complete a development plan and remain in a position of strength during negotiations.
SGLT2 Inhibitor, SBM-TFC-039 (Wanbang)
Wanbang Biopharmaceuticals recently provided a project update on the SGLT2 Inhibitor. We are very pleased to announce that they have completed most of the preclinical studies, the scale-up optimization and pharmaceutical grade manufacturing of the product. They will formulate the product in January 2017 to prepare for a clinical trial. Following that, they will conduct an additional pharmacology as well as toxicology study and file the “investigational new drug” (IND) package with the Chinese FDA (CFDA). This filing will trigger the next escalating milestone payment. Approval of the IND package by the CFDA will trigger another milestone payment and indicate the start of clinical studies.
The data that has been generated by Wanbang is currently being used in licensing discussions with a potential partner in India that recently approached us.
Skin Lightener, TFC-849 (Valeant) and Library
Our skin lightener, TFC-849 remains in scale-up at a French CRO for clinical studies. We did anticipate that this would be finalized earlier in 2016, however, the CRO experienced some complications and therefore it has been delayed until January. Valeant is aware of the delays in scale-up and has not altered plans to commercialize.
In 2016 we also completed the development of several other skin lighteners. This group contains potential lead compounds which can be licensed with TFC-1067 or separately in multiple markets. We have begun preliminary testing to determine the most effective new compounds, and expect results in Q1 2017.
Cell Preservation and Regenerative Compounds
We have now concluded testing of our glycoprotein compound library. We showed a protective effect in human fibroblasts (skin cells) under various stress conditions. Our subsidiary, TFChem has developed a comprehensive report of the data to be shared with potential partners. While the compounds have very interesting properties, they are still considered early stage, which means that the partnerships we seek will be considered “Research and Development” (R&D) collaborations. The compounds also have numerous potential applications and we need to take time to evaluate the best path to market. This is something we will advance with partner organizations.
One potential application is in storage of various cells and tissues. In May, we entered into a research program with Dr. Caigan Du’s laboratory (Vancouver Coastal Health Research Institute) on red blood cell storage and preservation. Results showed that while the compounds did not improve total blood cell count, they did improve the health of the cells that survived. This could result in more cells remaining viable in transfusions (where many typically die). Testing in commercial storage protocols will begin in 2017.
Dr. Du also carried out a study on oxidative stress in skin cells. The results confirmed what our previous CROs have found, which is a significant preservation under stress conditions. This data is currently being compiled and will be used for partnering discussions.
Acne Compound
Our acne compound is in chemistry development and expected to be completed and ready for testing in mid-2017. It will likely be our next major pipeline candidate. This project utilizes our successful business model of applying our proprietary technology to a known compound with stability issues. There is an excellent opportunity to produce a new therapy in this market which is estimated to be $8 Billion USD worldwide annually. Acne is the most common skin condition in the United States affecting some 50 million Americans and costing $3 Billion USD annually.
Keloid
We have developed a compound that we believe could have properties in preventing the formation of keloid scars. This is a significant unmet need as there are currently no effective therapies available. Early In vitro studies show a down-regulation of genes involved in the Extracellular Matrix (ECM) deposit which occurs in keloid scars and an up-regulation of genes involved in ECM degradation. Early safety tests have also been completed.
We have also uncovered mechanisms of action favourable to the target therapy and started to build a development plan for this project. Moreover, we are exploring CRO’s and universities in Europe with expertise in keloid research to assist us. The current market for global scar therapy is estimated at $16 Billion USD annually.
Like all biotech companies, we have experienced some delays in the development of our pipeline. We understand the apprehension that this can create for our investors and we want to assure you that we have a strong technology platform, a strong development pipeline, excellent patent protection and a dedicated management team. We are doing everything we can to sustainably increase shareholder value. We thank you for your continued support and look forward to what 2017 will bring.
Wishing you and your families Happy Holidays and all the best for 2017.
Sincerely,
Dr. Howard Verrico, CEO
- Published in News Home, Sirona Biochem
The Holy Grail of Skin Whitening Products – Expert Panel Discussion with Sirona Biochem
Sirona Biochem – The Holy Grail of Skin Whitening Products
– Momentum Public Relations –
September 22, 2016
Sirona Biochem (SBM:tsxv) is a proactive development and discovery stage based biotech firm with an R&D lab situated in Paris, France. The biotechnology enterprise is headquartered in Vancouver, British Columbia in Canada, and is world renowned for its state of the art fluorination chemistry technology. Their cutting edge platform is currently used to create cosmetic products that are both safe and effective for human use and consumption, as well as a plethora of pharmaceutical drugs.
Moreover, their leading edge compounds are either acquired by or licensed by multinational conglomerates in return for royalties, milestone payments, and/or marked upfront payments. It should also be noted that their platform focuses on the molecular stabilization of carbohydrates; which is noteworthy because carbohydrate based drugs are one of the most commonly prescribed drug families in the United States.
Notably, Sirona is currently working on what would be a company changing deal to license their newest compound, ‘Skin Lightener SBM-TFC-1067’. Globally, there is a growing trend for lighter skin in many parts of the world. Approximately 15{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of the world population invests in skin lightening products and the global market is expected to reach US$23 billion by 2020. Below is an excerpt from a recent CEO update explaining how they have a product that has garnered them serious interest from some of the world’s largest cosmetic / pharmaceutical companies.
Skin Lightener SBM-TFC-1067
SBM-TFC-1067 continues to attract the interest of global cosmetic companies, a list which continues to grow. A number of these companies completed material transfer agreements allowing them to test the compound in their facilities. We successfully scaled-up and produced over 1 kg of compound. In parallel, we completed independent testing in a 3D melanocyte model that mimics human skin. The results showed a strong skin lightener at low dosing without signs of toxicity. As this model is used by our potential partners to assess compounds, the study was key to obtaining independent results and improving our negotiating position. (view full CEO Update)
In addition, Sirona Biochem currently has two licensing agreements with two multi-billion dollar companies; namely Valeant Pharmaceuticals International (VRX:tsx) and Wanbang Biopharma.
The Annual General Meeting (AGM) was held yesterday in Vancouver, BC. Investors were clearly happy with what they heard. The stock price traded up on good volume. Management was very enthusiastic and are confident in their negotiations to secure a licensing deal with a global corporation for the Skin Lightening compound. For understandable reasons Management could not disclose details of their private discussions with the interested purchaser(s), however, the general consensus with investors is that Sirona (SBM:tsxv) is a Buy or at least a very enthusiastic hold.
The video below which was recently released will give you an in-depth look at this market and Sirona’s role in it. Spoiler Alert: First Berlin analyst Ellis Acklin explains their current price target of 98 cents for SBM. That’s a price target that excludes the potential SBM-TFC-1067 licensing deal. Keep in mind that as of today Sirona is only trading at 20 cents CND.
The Holy Grail of Skin Whitening Products – Expert Panel Discussion with Sirona Biochem
This message does not constitute investment advice. Momentum PR provides this material for convenience and information purposes only.
- Published in Bio technology, Blog, Sirona Biochem
Sirona Biochem (SBM:tsxv) CEO’s Report on Progress
Sirona Biochem CEO’s Report on Progress
– Momentum Public Relations – June 30, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) today provided a business update.
Dear Shareholders,
I would like to provide an update on our progress.
As we enter Q3, our resources continue to be focused on completing a license agreement for our skin lightener SBM-TFC-1067 with a global cosmetic company. While we initially anticipated a deal by the end of Q2, these types of agreements take time and we appreciate your patience. We are very confident in our ability to secure a licensing deal for SBM-TFC-1067.
Skin Lightener SBM-TFC-1067
SBM-TFC-1067 continues to attract the interest of global cosmetic companies, a list which continues to grow. A number of these companies completed material transfer agreements allowing them to test the compound in their facilities. We successfully scaled-up and produced over 1 kg of compound. In parallel, we completed independent testing in a 3D melanocyte model that mimics human skin. The results showed a strong skin lightener at low dosing without signs of toxicity. As this model is used by our potential partners to assess compounds, the study was key to obtaining independent results and improving our negotiating position.
Anti-Aging and Regenerative Compounds
We advanced our anti-aging and regenerative-medicine project by adding several compounds to our library which now consists of 16 novel compounds. With our lead compounds, we were able to show a protective effect in human fibroblast studies under stress conditions. Several global corporations have expressed interest and have signed material transfer agreements. These companies have been provided material for testing.
SGLT2 Inhibitor SBM-TFC-039
Wanbang Biopharmaceuticals has moved into pre-IND (Investigational New Drug) studies with SBM-TFC-039 for type 2 diabetes in China. Upon completion, Wanbang will file the IND with the CFDA. A successful filing will result in a $500,000 USD milestone payment for Sirona. We continue to work with Wanbang and provide technical support for the ongoing studies.
The company continues to maintain a healthy balance sheet and recently generated $829,500 as a result of a non-brokered private placement.
Looking back, over the last 12 months, Sirona Biochem has completed the following:
- Advanced discussions for a licensing deal for SBM-TFC-1067.
- Completed testing in a 3-D melanocyte skin model with excellent results.
- Obtained a milestone payment of $300,000 USD from Wanbang Biopharmaceuticals.
- Advanced the Obagi skin-lightening project.
- Increased the anti-aging and cell preservation library of compounds.
- Entered into material transfer agreements with various global companies for testing of the anti-aging/cell preservation library.
- Launched programs for Keloid scar and acne therapies.
- Launched a red blood cell preservation program.
- Presented at multiple global conferences with a focus on cosmetic ingredients.
Thank you for your continued support. Management remains confident that 2016 will be transformational for Sirona Biochem.
Sincerely,
Dr. Howard Verrico, CEO
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.
- Published in Life Sciences, News Home, Sirona Biochem
Sirona Biochem Announces Positive Safety and Efficacy Data for Innovative Skin Lightening Compound
Sirona Biochem Announces Positive Safety and Efficacy Data for Innovative Skin Lightening Compound SBM-TFC-1067 Accepted as Abstract Presentation by IMCAS
– Momentum Public Relations – June 16th, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) announced positive preclinical safety and efficacy data with SBM-TFC-1067 in a 3-D human skin-like model was accepted as an abstract for oral presentation by Sirona’s Chief Scientific Officer, Geraldine Deliencourt-Godefroy, at the IMCAS Asia Conference in Taipei on July 31, 2016.
Sirona has now demonstrated significant skin lightening in a model used by cosmetic scientists and leading cosmetic corporations around the world. In the study, SBM-TFC-1067, was topically applied daily to a MatTek Corps Melanoderm 3-D human skin model for 14 days using 3 different concentrations (0.1, 0.05 and 0.01{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}). Pigmentation was evaluated on days 0, 7, 11, and 14 using a chromameter to measure brightness (L*D65). Total melanin content was quantified after day 14. Results showed a statistically significant difference in surface reflectance with the 0.1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} and 0.05{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} concentrations of 1067. There was also a significant reduction of melanin quantity, which translates to visibly lighter skin.
The full abstract can be viewed on the IMCAS website here: http://www.imcas.com/en/attend/imcas-asia-2016/program/session/6150
“This is definitely good news for the millions of individuals around the world with hyperpigmentation or melasma”, said Attila Hajdu, Chief Business Development Officer of Sirona Biochem. “This exciting new data shows significant reduction in pigmentation without toxicity in human skin and being accepted as an abstract in the clinical dermatology stream at IMCAS is scientific validation.”
About IMCAS
Since its inception a decade ago, IMCAS has become one of the most important international programs dedicated to skin treatments. IMCAS Asia 2016, will bring together practitioners from across the Asia-Pacific region for informative and engaging exchanges. Over 2000 attendees and 80 exhibiting companies will come together for three days of intense learning in Taipei. Large cosmetic company representatives will also be in attendance to learn about the most innovative advances in the dermatology industry.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
About the Skin Lightening Project
Sirona Biochem’s French subsidiary TFChem received a $1.9 million grant in November 2011. This project is co-financed by the European Union and Europe Witnesses in Haute-Normandie with the support of the European Regional Development Fund (E.R.D.F.). A consortium of partners, including the University of Rouen (LMSM EA4312), contract research organization Biogalenys, and TFChem has been assembled to advance this project. The French government and EU are looking to promote and initiate collaborative projects that are focused on the development of new products and services containing a high level of innovation.
- Published in Business, Life Sciences, News Home, Sirona Biochem
Sirona (SBM:tsxv) Announces Wanbang to Proceed with Pre-IND and Milestone Payment
Sirona Biochem Announces Wanbang Biopharmaceuticals to Proceed to Pre-IND Testing and Receipt of $300,000 USD Milestone Payment
– Momentum Public Relations – June 13th, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) today announced that Wanbang Biopharmaceuticals has confirmed they will be proceeding with studies to prepare for Investigational New Drug (IND) filing for the anti-diabetic SGLT2 Inhibitor, SBM-TFC-039. IND filing and approval is required to proceed to clinical testing. Sirona Biochem has received a milestone payment of US$ 300,000 from Wanbang Biopharmaceuticals.
The set of studies, which will comprise of CMC (chemistry manufacturing and controls), sample preparation and any additional toxicology and pharmacokinetic studies, will be in accordance with the China Food and Drug Administration for enabling IND filing. Successful IND filing will result in a US$ 500,000 payment to Sirona Biochem as part of the US$ 9.5M in upfront and milestone payments according to the license contract with Wanbang Biopharmaceuticals.
“Based on promising results in our first set of studies, we will move the drug to the next phase and prepare for clinic trials,” said Ning Yuan, Vice President Business Development at Wanbang Biopharmaceuticals. “We are very pleased with the results and the productive collaboration with Sirona Biochem.”
“The advancement into pre-IND means that our partner is close to moving into the clinic with our SGLT2 inhibitor,” said Dr. Howard Verrico, CEO of Sirona Biochem. “This next step represents a significant achievement on this project as we continue toward commercialization in China and strengthen our negotiation position on global partnering. We look forward to continued success.”
About Wanbang Biopharmaceuticals
Wanbang Biopharmaceuticals is the leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Biopharmaceuticals is one of the largest manufacturers and marketers of a comprehensive portfolio of drugs for diabetes.
Wanbang Biopharmaceuticals is a subsidiary of Shanghai Pharmaceutical Group which is listed on the Shanghai Stock Exchange.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
- Published in Business, Life Sciences, News Home, Sirona Biochem
Sirona Biochem to Present New Test Results of SBM-TFC-1067 at Global Conferences
Sirona Biochem to Present New Test Results of SBM-TFC-1067 at Global Conferences
– Momentum Public Relations – May 17, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) is pleased to announce participation, in the form of presentations and exhibitions, in several global cosmetic industry conferences.
“Maintaining a strong presence in the global cosmetic industry is important as we continue to grow our pipeline and explore new areas of dermatology,” explained Attila Hajdu, Chief Business Development Officer of Sirona Biochem. “These conferences provide a great opportunity to conduct business with the key players in the industry in a timely and efficient manner.”
May 18-20: Attila Hajdu, Chief Business Development Officer of Sirona Biochem, will be exhibiting at China Beauty Expo in Shanghai and attending other business meetings in China and Korea. For more information on this conference, please visit: www.chinabeautyexpo.com/en
May 24-25: Dr. Geraldine Deliencourt-Godefroy, Chief Scientific Officer of Sirona Biochem, will present at COSM’innov 2016, the international congress on cosmetic science in Orléans France. CSOM’innov is where academia meets business as leading organizations seek the latest advances in the science of cosmetology. For more information on this conference, please visit: www.cosminnov.com
June 9-10: Attila Hajdu, Chief Business Development Officer of Sirona Biochem, will be presenting at the Innocos World Beauty Innovation Summit in Vienna, Austria. As a Gold Sponsor of the event, Sirona will have VIP access and dedicated 1:1 business meetings with senior executives from leading companies such as: Amore Pacific, Amway, Beiersdorf, Yves Rocher, Mirai Clinical, Sisley and Unilever. For more information on this conference, please visit: www.innocossummit.com
“As part of due diligence of a third party, our CRO performed additional safety and efficacy studies with our innovative skin lightening compound SBM-TFC-1067 in the last several weeks. The results are a major milestone that will significantly help us to close a licensing deal for this new compound in due course. Furthermore, it will provide scientific credibility enabling potential partners to initiate formulation and clinical trials required for approval of SBM-TFC-1067 in the major markets of the world (Japan, Korea, China, Europe and North America),” said Dr. Howard Verrico, CEO of Sirona Biochem.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant.
For more information please visit www.sironabiochem.com
- Published in Blog, News Home, Sirona Biochem
Sirona Biochem (SBM.V) Announces Close of Financing
Sirona Biochem Announces Close of Financing
– Momentum Public Relations – May 11, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) is pleased to announce that it has closed a private placement in the amount of 4,147,500 units at $0.20 per unit for total gross proceeds of $829,500. Each unit consists of one common share and one-half of one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of two years from the date of issue at a price of $0.30 per share.
The Company paid a total of $24,000 in finder’s fees in connection with the placement.
All securities issued under the placement are subject to statutory hold periods expiring on September 12, 2016.
Proceeds of the placement will be used for research and development purposes and for general working capital.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
- Published in News Home, Sirona Biochem